Workhuman Ignites Industry Momentum as the Undisputed Leader in Employee Recognition
FRAMINGHAM, Mass. & DUBLIN--(BUSINESS WIRE)--In a bold validation of its innovative approach to culture-building through employee recognition, Workhuman®, the world's leading employee recognition company, has been named the #1 vendor in employee recognition by G2 in their Spring 2025 Enterprise Grid® for Employee Recognition Software report and Star Performer in Everest Group's 2025 Rewards and Recognition (R&R) PEAK Matrix® Assessment. These dual accolades confirm what the market is already saying: when it comes to driving culture transformation and business performance through recognition, there is Workhuman—and then there is everyone else.
Recognition is evolving from a discretionary initiative to an integral part of talent management strategies.
Share
Purpose-Built for Impact, Not Just Points
Everest Group evaluated more than 30 vendors for its R&R Solutions PEAK Matrix and named Workhuman as the only Star Performer in the Leaders category. While others offer rewards programs dressed as culture platforms, Workhuman delivers the only true system of record for culture—anchored in behavioral data, AI-powered insights, and measurable outcomes that matter to the C-suite.
Everest Group cited Workhuman's innovation across AI and analytics as key drivers of its Star Performer designation. Here's why:
Inclusion Advisor: Real-time micro-coaching that reduces bias and transforms how people communicate—strengthening inclusion across every recognition moment.
Workhuman iQ: Embedded AI that delivers live, actionable workforce insights—helping leaders see trends, risks, and opportunities as they happen.
The Workhuman Store: The most expansive, personalized global rewards marketplace in the industry—driving higher redemption, deeper engagement, and lasting emotional impact.
In Everest Group's 2025 report, Workhuman was the only vendor named a 'Star Performer' among industry Leaders, recognized for unmatched innovation, pricing model transparency, and customer ROI.
"Recognition is evolving from a discretionary initiative to an integral part of talent management strategies. Workhuman has demonstrated strong capabilities in embedding AI-driven insights — including NLP-based skill inference and intelligent talent assistants — into its recognition and rewards solutions," says Priyanka Mitra, a Vice President at Everest Group. "Additionally, its ROI-based pricing model, combined with the Workhuman Guarantee, reinforces its focus on delivering measurable business outcomes, ensuring organizations see tangible value from their investments. Workhuman's advanced analytics, generative AI enhancements, and its integration with broader HR technology ecosystems contribute to its differentiated positioning. These strengths have supported Workhuman's placement as a Leader and Star Performer in Everest Group's R&R PEAK Matrix Assessment 2025."
Everest Group also named Workhuman a Major Contender in its 2025 Skills Intelligence Platforms PEAK Matrix®, the only recognition platform to earn this designation—validating the organization's ability to turn everyday appreciation into predictive talent insights.
Proof That Resonates: G2's #1 Spot (Again)
In parallel, for the sixth consecutive quarter, Workhuman has been ranked the #1 Employee Recognition Software by G2, the leading platform for peer-driven software reviews. With more than 1,600 verified customer reviews and consistent leadership across global markets, Workhuman continues to set the standard for excellence, trust, and impact in the recognition category.
More Than a Platform—A Strategic Advantage
'We're helping the most respected organizations in the world move beyond generic recognition,' said Grant Beckett, SVP of Corporate Strategy & Partnerships at Workhuman. 'These accolades from G2 and Everest Group reinforce what sets us apart: our platform is designed to improve performance, retention, and culture at scale—and we prove it with data and an ROI Guarantee.'
Recognition is no longer a 'nice to have.' It's the new engine of performance—and Workhuman is the only platform built to run it. As leaders look to drive culture at scale, unlock talent, and move the business forward, Workhuman gives them the visibility and velocity to lead with confidence.
About Workhuman
Workhuman® is the world's leading recognition and rewards platform, serving organizations of all sizes—from the Fortune 500 to fast-growing mid-market companies—across more than 180 countries. With over 25 years of category leadership, we support 7 million employees worldwide and have facilitated more than 100 million moments of connection that elevate culture and drive performance.
With over a decade of consistent profitability, Workhuman® stands as proof that investing in people delivers lasting business value. Our pioneering Human Intelligence™ technology transforms recognition into strategic insight, empowering organizations to unlock the full potential of their people while driving measurable business impact and culture transformation.
Learn more at www.workhuman.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
34 minutes ago
- CNBC
Two aerospace stocks are deeply overbought and could be due for a pullback
GE Aerospace and Howmet Aerospace are vulnerable to pullbacks after entering deep overbought territory this week. Each stock climbed more than 3% this week, outperforming the S & P 500 's 1.5% gain in the same period. The stocks have come so far so fast that now GE Aerospace and Howmet have the two highest 14-day relative strength index, or RSI, readings in the S & P 500. CNBC Pro used its stock screener tool available for subscribers to find the most oversold stocks as measured by the 14-day RSI. Stocks that have a 14-day RSI above 70 are viewed as overbought, leaving them susceptible to a decline, while those a 14-day RSI below 30 are often thought of as oversold, suggesting they may see a bounce. GE Aerospace has now risen for nine straight weeks, while Howmet has advanced for seven. GE Aerospace is ahead more than 53% year to date, while Howmet is up more than 60%. While the typical analyst polled by LSEG has buy ratings on both companies, the consensus 12-month price target foresees more than 5% downside for each stock over the next year following these big runs. Here's the full list of S & P 500 stocks with the highest 14-day RSIs, along with what Wall Street thinks of them, according to LSEG data as of Friday morning: At the other extreme, Brown-Forman is the most oversold name in the S & P 500 with a 14-day RSI below 22. Shares of the Jack Daniel's whiskey distiller tumbled nearly 16% this week. Much of the decline came after Brown-Forman posted revenue and net income for its fiscal fourth quarter that missed analysts' consensus forecasts, according to consensus LSEG numbers. The Louisville-based company said it was operating in an "exceptionally challenging macroeconomic environment." The stocks has slumped 37% in the past six months and is on pace to record its fifth consecutive down year. Although Wall Street analysts rate Brown-Forman no more than a collective "hold," the consensus 12-month price target as compiled by LSEG suggests shares may rally 35%. Brown-Forman also has a dividend yield of 3.32%. Here are the other stocks with 14-day RSIs below 30, along with what Wall Street sees for them:
Yahoo
37 minutes ago
- Yahoo
State Thruway Authority OKs added funds for firm handling Seneca Nation lawsuit
ALBANY — New York State Thruway Authority officials have agreed to increase by $1 million the payment cap on a contract with the Buffalo-based law firm that is representing the public agency in an ongoing legal dispute with the Seneca Nation of Indians. During a meeting on Tuesday, members of the authority's board of directors unanimously authorized an amendment to an existing contract with Nixon Peabody that will raise the maximum amount payable to the law firm to $1.8 million. The authority's original 2022 agreement capped the amount to be paid to Nixon Peabody at $800,000. The resolution supporting the move notes that Nixon Peabody has provided 'substantial services' pertaining to ongoing litigation involving the Seneca Nation. Seneca leaders filed a lawsuit in 2018 claiming that the state agency failed to obtain the necessary federal approvals for an easement that has allowed the thruway to run through the tribe's Cattaraugus territory for decades. The Nation's lawsuit seeks to compel the state authority to obtain a new easement or compensate the Nation for tolls collected from motorists using the authority on reservation land. It also seeks to end toll collection along the roughly 3-mile section of the thruway, which is about 30 miles south of Buffalo. In 2023, the U.S. Court of Appeals for the Second District allowed the lawsuit to continue after it rejected an attempt by the state to have it dismissed. The decision upheld a 2020 U.S. District Court ruling. The resolution supporting the pay increase for Nixon Peabody notes that the law firm has provided 'substantial services' pertaining to the litigation over the easement while also serving as bond counsel for authority debt transactions that are reimbursable by the state. The resolution describes the Seneca litigation as 'complex' while indicating that there is also a 'continued need for support' with the authority's state debt transactions.
Business Upturn
an hour ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
